Tasquinimod for the Treatment of Relapsed or Refractory Myeloma

NCT04405167 ↗

Phase 1 Terminated 30 enrolled University of Pennsylvania Active Biotech AB · collab

Non-randomizedSequentialOpen-labelTreatment

Summary

This study is the first study of tasquinimod, an inhibitor of S100A9, in patients with multiple myeloma.

Timeline

Start: 2020-07-10
Primary completion: 2025-05-19
Completion: 2025-07-01

Outcome

Outcome not reported

Stopped (Enrollment): “Slow accrual at the time when sufficient participants were already enrolled to answer the scientific question posed by the study.”

Publications

Fan R, Satilmis H, Vandewalle N, Verheye E, Vlummens P, Maes A, Muylaert C, De Bruyne E, Menu E, Evans H, Chantry A, De Beule N, Hose D, Torngren M, Eriksson H, Vanderkerken K, Maes K, Breckpot K, De Veirman K. Tasquinimod suppresses tumor cell growth and bone resorption by targeting immunosuppressive myeloid cells and inhibiting c-MYC expression in multiple myeloma. J Immunother Cancer. 2023 Jan;11(1):e005319. doi: 10.1136/jitc-2022-005319.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Tasquinimod	Small molecule	—	Oral
Background	Dexamethasone	Small molecule	—	—
Background	Ixazomib	Unknown	—	—
Background	Lenalidomide	Other / unclassified	—	—